Helicobacter pylori is one of the most common chronic bacterial infections in the world and one of the most examined topics in gastroenterology, including the European Board examination. This overview covers the concepts candidates and practising physicians are expected to know.
What it is
H. pylori is a Gram-negative, spiral, urease-producing bacterium that colonises the gastric mucosa. Infection is usually acquired in childhood and persists for life unless eradicated. Prevalence is highest in lower-income settings and in older generations.
Associated conditions
- Chronic active gastritis, present in almost everyone infected.
- Duodenal and gastric peptic ulcer disease.
- Gastric adenocarcinoma, for which H. pylori is classified as a group 1 carcinogen.
- Gastric MALT lymphoma.
- Iron deficiency anaemia and immune thrombocytopenia in some patients.
Testing
Non-invasive tests include the urea breath test and the stool antigen test. At endoscopy, the rapid urease test, histology and culture can be used. Proton pump inhibitors and recent antibiotics reduce the sensitivity of the breath, stool and urease tests, so the timing of testing in relation to these medicines matters and is a frequent exam question. Serology shows past exposure and cannot confirm current infection.
Antibiotic resistance
Resistance, particularly to clarithromycin and metronidazole, varies between regions and has increased over time. This is why local resistance data and confirmation of eradication after therapy are emphasised in guidelines such as the Maastricht consensus.
For the exam
Expect questions on which test to use and when, the conditions linked to infection, the significance of a positive test in a patient on a proton pump inhibitor, and the role of H. pylori in gastric cancer and MALT lymphoma.